Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. Stark Considering Making Medicare’s Protected Drug Classes Permanent

Executive Summary

Pete Stark, D-Calif., is floating a proposal to turn into a statutory requirement the CMS guidance that Part D plans must cover "all or substantially all" drugs in six classes

You may also be interested in...



Part D’s Six Protected Drug Classes May Ride Baucus Medicare Vehicle

A statutory requirement that Medicare Part D drug plans cover "all or substantially all" drugs in six classes stands a good chance of making it into the Senate Finance Committee's upcoming Medicare physician payment package

Part D’s Six Protected Drug Classes May Ride Baucus Medicare Vehicle

A statutory requirement that Medicare Part D drug plans cover "all or substantially all" drugs in six classes stands a good chance of making it into the Senate Finance Committee's upcoming Medicare physician payment package

Benzodiazepine Coverage Among Medicare Provisions In Child Health Bill

Makers of benzodiazepines could see wider use of their products by Medicare Part D enrollees, under a provision of the child health/Medicare legislative package that cleared the House Ways and Means Committee July 27

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel